Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EPS (Basic) (2021 - 2025)

Historic EPS (Basic) for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $0.25.

  • Kiniksa Pharmaceuticals International's EPS (Basic) rose 23888.89% to $0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.49, marking a year-over-year increase of 47692.31%. This contributed to the annual value of -$0.6 for FY2024, which is 40236.97% down from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's EPS (Basic) stood at $0.25, which was up 23888.89% from $0.24 recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year EPS (Basic) high stood at $3.23 for Q3 2022, and its period low was -$0.72 during Q1 2021.
  • Its 5-year average for EPS (Basic) is $0.09, with a median of -$0.18 in 2023.
  • In the last 5 years, Kiniksa Pharmaceuticals International's EPS (Basic) skyrocketed by 83409.09% in 2022 and then plummeted by 13456.66% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EPS (Basic) (Quarter) stood at -$0.52 in 2021, then soared by 345.37% to $1.28 in 2022, then tumbled by 71.79% to $0.36 in 2023, then plummeted by 134.57% to -$0.12 in 2024, then surged by 300.9% to $0.25 in 2025.
  • Its EPS (Basic) stands at $0.25 for Q3 2025, versus $0.24 for Q2 2025 and $0.12 for Q1 2025.